{"id":"rhenium-188-hedp","safety":{"commonSideEffects":[{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Transient increase in bone pain (flare)"},{"rate":null,"effect":"Hematologic toxicity"}]},"_chembl":{"chemblId":"CHEMBL295441","moleculeType":"Small molecule","molecularWeight":"627.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rhenium-188 is a beta-emitting radionuclide complexed with HEDP (1,1-hydroxyethylidene diphosphonate), a bone-seeking bisphosphonate analog. The complex accumulates in osteoblastic bone lesions with high metabolic activity, delivering localized radiation therapy to metastatic bone disease. This approach combines the targeting specificity of bone-seeking agents with the therapeutic effects of beta radiation.","oneSentence":"Rhenium-188-HEDP is a radiopharmaceutical that localizes to areas of increased bone metabolism and delivers beta radiation directly to bone lesions for pain palliation and potential therapeutic benefit.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:24.876Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic bone pain from osteoblastic bone lesions"},{"name":"Bone metastases in cancer patients"}]},"trialDetails":[{"nctId":"NCT03458559","phase":"PHASE3","title":"Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2018-05-16","conditions":"Prostate Cancer Metastatic to Bone","enrollment":402}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Re-188-HEDP","188Rhenium-etidronate"],"phase":"phase_3","status":"active","brandName":"Rhenium-188-HEDP","genericName":"Rhenium-188-HEDP","companyName":"Amsterdam UMC, location VUmc","companyId":"amsterdam-umc-location-vumc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rhenium-188-HEDP is a small molecule used in the treatment of prostate cancer metastatic to bone. It is being studied in clinical trials, including NCT03458559, as a potential treatment option for patients with advanced prostate cancer refractory to hormonal therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}